Company: RPTX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-103764
Chunk: 15

Company: Repare Therapeutics Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 15
---
 M.D., whose terms will expire at the upcoming Annual Meeting;•Class III, which consists of Samarth Kulkarni, Ph.D. and Steve Forte, whose terms will expire at the Annual Meeting of Shareholders to be held in 2026; and•Class I, which consists of Susan M. Molineaux, Ph.D. and Ann D. Rhoads, whose terms will expire at the Annual Meeting of Shareholders to be held in 2027.Each class consists, as nearly as possible, ofone-thirdof the total number of directors, and each class has a three-year term. At each annual meeting of shareholders, the successors to directors whose terms then expire will be elected to serve from the time of election until the third annual meeting following the election. Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist ofone-thirdof the directors. Vacancies on the board of directors may be filled only by persons elected by a majority of the remaining directors. A director elected by the board of directors to fill a vacancy in a class, including vacancies created by an increase in the number of directors, shall serve for the remainder of the full term of that class and until the director’s successor is duly elected and qualified. The division of our board of directors into three classes with staggered three-year terms may delay or prevent a change of our management or a change in control of Repare.Dr. Bonita, Mr. Civik, Ms. Schafer and Dr. Stein are each current members of our board of directors and each of whom has been nominated for reelection to serve as a Class II director. Dr. Bonita, Mr. Civik and Ms. Schafer were previously elected to our board of directors by our shareholders. Dr. Stein was appointed to our board of directors in June 2024 to fill a vacancy on the board created by a director resignation. Each of Dr. Bonita, Mr. Civik, Ms. Schafer and Dr. Stein has agreed to stand forre-electionat the Annual Meeting, and our management has no reason to believe that any of these nominees will be unable to serve. If elected at the Annual Meeting, each of Dr. Bonita, Mr. Civik, Ms. Schafer and Dr. Stein would serve until the Annual Meeting of Shareholders to be held in 2028 and until such director’s successor has been duly elected, or